Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: A Combination Study of CAR-T Therapy in r/r B-NHL [Phase 2]
A Phase 2 clinical trial update on a CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma, specifically diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors [Phase 2]
Phase 2 trial evaluating zanubrutinib with R-CHOP for newly diagnosed diffuse large B-cell lymphoma with high-risk factors.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
Phase 2 trial comparing subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated CD20-positive diffuse la…
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma [Phase 3]
Phase 3 trial investigating autologous anti-CD19 CAR-T cells given with a BTK inhibitor for B cell lymphomas, with an unspecified status.
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]
Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 prospective clinical study updating on ZPR regimen in elderly treatment-naive diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 prospective clinical study of the ZPR regimen in relapsed/refractory diffuse large B-cell lymphoma is being reported.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of itacitinib (INCB039110) in combination with ibrutinib in relapsed/refractory diffuse large B-cell lymphoma has completed …
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and rela…
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk [Phase 3]
Phase 3 trial comparing 4R-CHOP+4R to 6R-CHOP+2R in newly diagnosed diffuse large B-cell lymphoma patients; status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-05-23Clinical Trial Update: The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years [Phase 3]
Phase 3 clinical trial comparing ZR2 to R-miniCHOP in unfit or frail de novo diffuse large B-cell lymphoma patients aged 70 or older; status…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Decitabine and Anti-PD-1 in R/R DLBCL [Phase 2]
Phase 2 trial investigating decitabine in combination with anti-PD-1 for relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment [NA]
A completed clinical trial assessing a Mobile Health Case Management System aimed at reducing treatment abandonment in pediatric cancer sett…
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy [Phase 2]
Phase II clinical trial investigating rituximab, chidamide, zanubrutinib-induced and CHOP therapy for double expressor diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients [Phase 2]
Phase 2 trial evaluating chidamide, azacitidine in combination with GM regimen for relapsed/refractory diffuse large B-cell lymphoma.
-
FDA approval · 2023-04-19FDA Approved: POLIVY — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for POLIVY (polatuzumab vedotin) from Genentech, Inc., updating its labeling and/or approved indicat…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma [Phase 3]
Phase III trial assessing SyB L-0501 with Rituximab in recurrent/relapsed diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma [Phase 4]
A Phase 4 clinical trial update evaluating selinexor in combination with R-GemOx as second-line therapy for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]
Phase II study evaluating oral panobinostat (LBH589) in combination with rituximab for diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Genotype-guided Treatment in DLBCL [Phase 3]
Phase 3 clinical trial updating genotype-guided treatment for Diffuse Large B Cell Lymphoma (DLBCL) is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma [Phase 1, Phase 2]
Clinical trial updates the combination of obinutuzumab with lenalidomide for relapsed/refractory follicular and aggressive B-cell lymphomas,…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial update for TC-110 T cells in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia (comple…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Umbilical Cord Blood NK cells with Rituximab, high-dose chemotherapy, and stem cell transplant in recurrent or refr…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial assessing survival and autonomy in elderly relapsed diffuse large B-cell lymphoma patients treated with Rituximab plus chemoth…